ResMed (NYSE:RMD) Shares Gap Down – Time to Sell?

Posted by Francis Steltz on Jul 13th, 2026

ResMed Inc. (NYSE:RMD – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $203.87, but opened at $193.72. ResMed shares last traded at $199.27, with a volume of 282,707 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have commented on RMD. Jefferies Financial Group cut their target price on ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a report on Friday. KeyCorp lowered their price objective on ResMed from $290.00 to $266.00 and set an “overweight” rating for the company in a research report on Monday, June 22nd. Citigroup reaffirmed a “neutral” rating and issued a $235.00 price objective (down from $270.00) on shares of ResMed in a research note on Sunday. Wells Fargo & Company decreased their target price on shares of ResMed from $227.00 to $225.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 8th. Finally, Morgan Stanley restated an “equal weight” rating and set a $230.00 price target (down from $286.00) on shares of ResMed in a report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $260.17.

View Our Latest Report on RMD

ResMed Trading Down 2.4%

The firm has a 50-day moving average of $200.46 and a 200 day moving average of $228.14. The company has a market cap of $28.86 billion, a P/E ratio of 19.19, a price-to-earnings-growth ratio of 1.22 and a beta of 0.78. The company has a current ratio of 3.01, a quick ratio of 2.33 and a debt-to-equity ratio of 0.06.

ResMed (NYSE:RMD – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.07. The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company’s revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.37 earnings per share. On average, analysts predict that ResMed Inc. will post 11.13 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Thursday, May 14th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, May 14th. This represents a $2.40 annualized dividend and a yield of 1.2%. ResMed’s dividend payout ratio is currently 23.14%.

Insider Buying and Selling

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total value of $1,090,783.05. Following the completion of the sale, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at approximately $101,893,036.65. The trade was a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 14,973 shares of company stock valued at $3,096,067 in the last ninety days. Company insiders own 0.65% of the company’s stock.

Institutional Trading of ResMed

Several large investors have recently made changes to their positions in the company. Hsbc Holdings PLC raised its stake in shares of ResMed by 17.6% in the fourth quarter. Hsbc Holdings PLC now owns 328,785 shares of the medical equipment provider’s stock worth $79,321,000 after purchasing an additional 49,253 shares during the last quarter. Nordea Investment Management AB grew its holdings in ResMed by 37.2% during the fourth quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock worth $262,027,000 after buying an additional 294,124 shares in the last quarter. Goldman Sachs Group Inc. raised its position in ResMed by 13.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 979,087 shares of the medical equipment provider’s stock valued at $235,833,000 after buying an additional 118,296 shares during the last quarter. Fideuram Asset Management Ireland dac bought a new position in ResMed during the 4th quarter valued at $4,712,000. Finally, Regatta Capital Group LLC bought a new position in ResMed during the 4th quarter valued at $2,508,000. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Company Profile

(Get Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.